Fifth Third Bancorp
TAK icon

Fifth Third Bancorp’s Takeda Pharmaceutical TAK Stock Holding History

Fifth Third Bancorp’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.9K Sell
3,361
-154
-4% -$2.55K ﹤0.01% 3197
2026
Q1 		$65.1K Buy
3,515
+211
+6% +$3.7K ﹤0.01% 3094
2025
Q4 		$51.5K Sell
3,304
-842
-20% -$12K ﹤0.01% 1453
2025
Q3 		$60.7K Sell
4,146
-1,501
-27% -$22.3K ﹤0.01% 1413
2025
Q2 		$87.3K Buy
5,647
+415
+8% +$6.13K ﹤0.01% 1205
2025
Q1 		$77.8K Buy
5,232
+2,411
+85% +$33.8K ﹤0.01% 1248
2024
Q4 		$37.4K Buy
2,821
+619
+28% +$8.5K ﹤0.01% 1503
2024
Q3 		$31.3K Buy
2,202
+128
+6% +$1.82K ﹤0.01% 1611
2024
Q2 		$26.8K Sell
2,074
-551
-21% -$7.29K ﹤0.01% 1625
2024
Q1 		$36.5K Buy
2,625
+691
+36% +$10K ﹤0.01% 1483
2023
Q4 		$27.6K Hold
1,934
– – ﹤0.01% 1652
2023
Q3 		$29.9K Sell
1,934
-532
-22% -$8.24K ﹤0.01% 1567
2023
Q2 		$38.7K Buy
2,466
+571
+30% +$9.36K ﹤0.01% 1465
2023
Q1 		$31.2K Buy
1,895
+455
+32% +$7.25K ﹤0.01% 1644
2022
Q4 		$22.5K Sell
1,440
-237
-14% -$3.31K ﹤0.01% 1659
2022
Q3 		$22K Buy
1,677
+638
+61% +$8.87K ﹤0.01% 1657
2022
Q2 		$15K Buy
1,039
+376
+57% +$5.37K ﹤0.01% 1863
2022
Q1 		$9K Sell
663
-65
-9% -$954 ﹤0.01% 2105
2021
Q4 		$10K Sell
728
-878
-55% -$12.3K ﹤0.01% 2104
2021
Q3 		$26K Sell
1,606
-283
-15% -$4.75K ﹤0.01% 1696
2021
Q2 		$32K Sell
1,889
-6,278
-77% -$107K ﹤0.01% 1628
2021
Q1 		$149K Buy
8,167
+87
+1% +$1.56K ﹤0.01% 1041
2020
Q4 		$147K Sell
8,080
-606
-7% -$10.6K ﹤0.01% 1033
2020
Q3 		$155K Sell
8,686
-460
-5% -$8.38K ﹤0.01% 964
2020
Q2 		$164K Sell
9,146
-1,871
-17% -$33.6K ﹤0.01% 934
2020
Q1 		$167K Buy
11,017
+1,188
+12% +$21.5K ﹤0.01% 889
2019
Q4 		$194K Buy
9,829
+509
+5% +$9.74K ﹤0.01% 953
2019
Q3 		$160K Sell
9,320
-2,387
-20% -$41.3K ﹤0.01% 979
2019
Q2 		$207K Sell
11,707
-3,018
-20% -$54.9K ﹤0.01% 904
2019
Q1 		$300K Buy
14,725
+14,681
+33,366% +$295K ﹤0.01% 766
2018
Q4 		$1K Buy
+44
New +$743 ﹤0.01% 2183

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Fifth Third Bancorp's TAK Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Takeda Pharmaceutical (TAK) stake by 4.4% in Q2 2026, selling an estimated $2.55K and leaving 3,361 shares worth $53.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

Fifth Third Bancorp first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $300K in Q1 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Fifth Third Bancorp held 3,361 shares of Takeda Pharmaceutical worth $53.9K as of Q2 2026.
  • Fifth Third Bancorp sold 154 Takeda Pharmaceutical shares in Q2 2026, an estimated $2.55K.
  • Takeda Pharmaceutical made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3197 holding.
  • Fifth Third Bancorp first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
  • Fifth Third Bancorp's Takeda Pharmaceutical position peaked at $300K in Q1 2019.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.